European Society of Cardiology (ESC)

This page includes news from the European Society of Cardiology (ESC). The ESC represents more than 95,000 men and women in the field of cardiology from Europe, the Mediterranean basin. It is the European umbrella cardiology organization, which includes the European Association of Percutaneous Cardiovascular Interventions (EAPCI), which hosts the large EuroPCR meeting; the European Heart Rhythm Society (EHRA); European Association of Cardiovascular Imaging (EACVI); European Association of Preventive Cardiology (EAPC); and the Association for Acute Cardiovascular Care (ACVC).

No sedation required: Local anesthesia enough for most TAVR patients
New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary.
Abbott receives expanded approval for Navitor TAVR system
Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.
The most anticipated trials at ESC 2025
The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.
‘This trend is encouraging’: Radial access for PCI now preferred in US
In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on.
Vaccines—for the flu, COVID-19 and other infections—are a ‘foundational pillar’ of heart protection
Staying vaccinated as recommended by doctors can help patients limit their risk of adverse cardiovascular events, according to a new consensus statement published in European Heart Journal.

No sedation required: Local anesthesia enough for most TAVR patients

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary.

Abbott receives expanded approval for Navitor TAVR system

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

ESC Congress 2022 European Society of Cardiology

The most anticipated trials at ESC 2025

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

‘This trend is encouraging’: Radial access for PCI now preferred in US

In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on.

COVID-19 vaccine vaccination myocarditis heart damage inflammation RSNA imaging radiology cardiology

Vaccines—for the flu, COVID-19 and other infections—are a ‘foundational pillar’ of heart protection

Staying vaccinated as recommended by doctors can help patients limit their risk of adverse cardiovascular events, according to a new consensus statement published in European Heart Journal.

Next-day discharge after TAVR is still safe when alternative access is required

Even TAVR patients not treated using transfemoral access can typically go home the very next day.

doctor patient elderly check up hospital

2 out of 5 heart failure patients are not seeing a cardiologist

Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.

High Lp(a) levels increase risk of repeat cardiovascular events—LDL drugs may help

Researchers evaluated data from more than 273,000 patients with a history of ASCVD, noting that higher Lp(a) levels are consistently linked to worse cardiovascular outcomes.